Investigative Medicine Division
We aim to rapidly translate innovative science into patient benefit across a range of disease areas. From molecular biology and target discovery, through to interventional medicine and informing policy, we bring together researchers in a diverse range of specialties including acute stroke, dementia and immunology.
Molecular Basis for the Recognition of HIV Nef138-8 Epitope by a Pair of Human Public T Cell Receptors.
Ma K. et al, (2022), J Immunol
Major haemorrhage: past, present and future.
Shah A. et al, (2022), Anaesthesia
IFITM3 restricts virus-induced inflammatory cytokine production by limiting Nogo-B mediated TLR responses.
Clement M. et al, (2022), Nat Commun, 13
Lymphatic endothelia stakeout cryptic stem cells.
Antanaviciute A. et al, (2022), Cell Stem Cell, 29, 1292 - 1293
Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction.
Hadjihambi A. et al, (2022), J Hepatol
6 July 2022
Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.
Strong cytotoxic T cell responses to an internal viral component are associated with mild COVID-19 disease
1 December 2021
Study from the Dong Group reveals key differences in the adaptive immune responses of patients with mild vs. severe COVID-19, highlighting a potential new vaccine target.
29 September 2022
The Royal Microscopical Society awards celebrate the best in microscopy, recognising those making a special contribution to microscopy, cytometry and imaging.
5 August 2022
Co-founded by Simon Davis, MiroBio focuses on developing therapeutics for inflammatory diseases.